Adenosine A2A receptor null chondrocyte transcriptome resembles that of human osteoarthritic chondrocytes.


Journal

Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499

Informations de publication

Date de publication:
09 2021
Historique:
received: 10 02 2021
accepted: 08 04 2021
pubmed: 12 5 2021
medline: 19 2 2022
entrez: 11 5 2021
Statut: ppublish

Résumé

Adenosine signaling plays a critical role in the maintenance of articular cartilage and may serve as a novel therapeutic for osteoarthritis (OA), a highly prevalent and morbid disease without effective therapeutics in the current market. Mice lacking adenosine A2A receptors (A2AR) develop spontaneous OA by 16 weeks of age, a finding relevant to human OA since loss of adenosine signaling due to diminished adenosine production (NT5E deficiency) also leads to development of OA in mice and humans. To better understand the mechanism by which A2AR and adenosine generation protect from OA development, we examined differential gene expression in neonatal chondrocytes from WT and A2AR null mice. Analysis of differentially expressed genes was analyzed by KEGG pathway analysis, and oPOSSUM and the flatiron database were used to identify transcription factor binding enrichment, and tissue-specific network analyses and patterns were compared to gene expression patterns in chondrocytes from patients with OA. There was a differential expression of 2211 genes (padj<0.05). Pathway enrichment analysis revealed that pro-inflammatory changes, increased metalloprotease, reduced matrix organization, and homeostasis are upregulated in A2AR null chondrocytes. Moreover, stress responses, including autophagy and HIF-1 signaling, seem to be important drivers of OA and bear marked resemblance to the human OA transcriptome. Although A2AR null mice are born with grossly intact articular cartilage, we identify here the molecular foundations for early-onset OA in these mice, further establishing their role as models for human disease and the potential use of adenosine as a treatment for human disease.

Identifiants

pubmed: 33973110
doi: 10.1007/s11302-021-09788-5
pii: 10.1007/s11302-021-09788-5
pmc: PMC8410926
doi:

Substances chimiques

Adora2a protein, mouse 0
Receptor, Adenosine A2A 0
Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

439-448

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM136573
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR056672
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000038
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR054897
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Arthritis Rheum. 2003 Mar;48(3):700-8
pubmed: 12632423
Oxid Med Cell Longev. 2014;2014:541230
pubmed: 24876913
Purinergic Signal. 2016 Sep;12(3):537-47
pubmed: 27289226
Nat Rev Rheumatol. 2016 Jul;12(7):412-20
pubmed: 27192932
Arthritis Rheum. 2009 Aug;60(8):2340-9
pubmed: 19644890
J Am Acad Orthop Surg. 2013;21 Suppl 1:S1-6
pubmed: 23818185
Sci Transl Med. 2018 Feb 14;10(428):
pubmed: 29444976
PLoS One. 2014 Nov 12;9(11):e112735
pubmed: 25390621
Inflammation. 2018 Aug;41(4):1135-1141
pubmed: 29656316
Cell Death Dis. 2018 Mar 2;9(3):360
pubmed: 29500414
Sci Rep. 2021 Jan 13;11(1):968
pubmed: 33441836
J Cell Physiol. 2008 Sep;216(3):708-15
pubmed: 18366089
Am J Manag Care. 2009 Sep;15(8 Suppl):S230-5
pubmed: 19817509
Dev Cell. 2018 Jan 22;44(2):139-163
pubmed: 29401418
J Cell Sci. 2007 Feb 1;120(Pt 3):385-93
pubmed: 17251379
Trans Am Clin Climatol Assoc. 2017;128:44-54
pubmed: 28790486
Arthritis Rheum. 2004 Dec;50(12):3915-24
pubmed: 15593204
Nat Rev Rheumatol. 2011 Aug 02;7(10):579-87
pubmed: 21808292
Arthritis Rheum. 2010 Mar;62(3):791-801
pubmed: 20187128
Osteoarthritis Cartilage. 2016 Feb;24(2):196-205
pubmed: 26190795
Osteoarthritis Cartilage. 2009 Aug;17(8):971-9
pubmed: 19303469
Sports Health. 2018 Nov/Dec;10(6):500-514
pubmed: 29543576
Free Radic Biol Med. 2018 Oct;126:122-132
pubmed: 30096432
Science. 2009 Feb 6;323(5915):793-7
pubmed: 19131594
FASEB J. 2019 Jun;33(6):7555-7562
pubmed: 30866652
G3 (Bethesda). 2012 Sep;2(9):987-1002
pubmed: 22973536
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Oncogene. 2006 Dec 4;25(57):7492-504
pubmed: 17143293
Nat Rev Rheumatol. 2011 Mar;7(3):161-9
pubmed: 21200395
Br J Pharmacol. 2016 Dec;173(23):3279-3291
pubmed: 27595240
J Exp Med. 2004 Dec 6;200(11):1395-405
pubmed: 15583013
Int J Mol Sci. 2019 Aug 03;20(15):
pubmed: 31382554
Curr Opin Rheumatol. 2011 Sep;23(5):492-6
pubmed: 21709557
Methods Mol Med. 2004;100:1-14
pubmed: 15280583
Tissue Eng Part B Rev. 2010 Feb;16(1):105-15
pubmed: 19831641
Mitochondrion. 2004 Sep;4(5-6):715-28
pubmed: 16120427
Hypertension. 2004 Nov;44(5):649-54
pubmed: 15452028
Mitochondrion. 2002 Feb;1(4):301-19
pubmed: 16120285
Semin Arthritis Rheum. 2015 Apr;44(5):531-541
pubmed: 25511476
Pancreas. 2020 Feb;49(2):193-200
pubmed: 32011529
N Engl J Med. 2011 Feb 3;364(5):432-42
pubmed: 21288095
Sci Rep. 2020 Aug 10;10(1):13477
pubmed: 32778777
Osteoarthritis Cartilage. 2018 Nov;26(11):1531-1538
pubmed: 30081074
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13915-20
pubmed: 16169904
Biochem Pharmacol. 2020 Apr;174:113784
pubmed: 31884043
Nat Commun. 2017 May 11;8:15019
pubmed: 28492224
J Clin Rheumatol. 2015 Jun;21(4):216-20
pubmed: 26010187
Nat Commun. 2015 Apr 28;6:7014
pubmed: 25916556
Sci Rep. 2013;3:2683
pubmed: 24042188
FASEB J. 2020 Apr;34(4):5027-5045
pubmed: 32052890
Am J Pathol. 2017 Sep;187(9):1935-1944
pubmed: 28667836
Exp Ther Med. 2019 Dec;18(6):4231-4240
pubmed: 31772626
Pflugers Arch. 2008 Jan;455(4):563-73
pubmed: 17849146
FASEB J. 2017 Jul;31(7):3116-3125
pubmed: 28389425

Auteurs

Cristina M Castro (CM)

Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Boston, MA, USA.

Carmen Corciulo (C)

Division of Translational Medicine, NYUGSOM, New York, NY, USA.
Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutritional, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

Benjamin Friedman (B)

Department of Medicine, Division of Rheumatology, NYUGSOM, New York, NY, USA.

Zhi Li (Z)

Institute for Systems Genetics, NYU Langone Health, New York, NY, USA.
Department of Biochemistry and Molecular Pharmacology, NYU Langone Health, New York, NY, USA.

Samson Jacob (S)

Institute for Systems Genetics, NYU Langone Health, New York, NY, USA.

David Fenyo (D)

Institute for Systems Genetics, NYU Langone Health, New York, NY, USA.
Department of Biochemistry and Molecular Pharmacology, NYU Langone Health, New York, NY, USA.

Bruce N Cronstein (BN)

Department of Medicine, Division of Rheumatology, NYUGSOM, New York, NY, USA. bruce.cronstein@nyumc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH